Avacopan

CAS No.	1346623-17-3
MDL No.	MFCD28502293
MF	C₃₃H₃₅F₄N₃O₂
MW	581.60
InChI Key	PUKBOVABABRILL-YZNIXAGQSA-N

CUSTOM SYNTHESIS PRECLINICAL SUPPORT

Pricing & Availability

Pack Size	Purity	Price	Availability	Action
-	-	On Request	On Request
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.	1346623-17-3
Product Name	Avacopan

Biological Targets

C5AR1

Associated Conditions

microscopic polyangiitis·Granulomatosis with Polyangiitis·hidradenitis suppurativa·anti-neutrophil cytoplasmic antibody-associated vasculitis·liver disease·

* The information provided here is compiled from public sources and is for reference only.

Avacopan

CAS No.	1346623-17-3
MDL No.	MFCD28502293
MF	C₃₃H₃₅F₄N₃O₂
MW	581.60
InChI Key	PUKBOVABABRILL-YZNIXAGQSA-N

CUSTOM SYNTHESIS PRECLINICAL SUPPORT

Pricing & Availability

Pack Size	Purity	Price	Availability	Action
-	-	On Request	On Request
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.	1346623-17-3
Product Name	Avacopan

Biological Targets

C5AR1

Associated Conditions

microscopic polyangiitis·Granulomatosis with Polyangiitis·hidradenitis suppurativa·anti-neutrophil cytoplasmic antibody-associated vasculitis·liver disease·

* The information provided here is compiled from public sources and is for reference only.

Avacopan

Pricing & Availability

Product Information

Biological Profile

Safety Information

Properties

Biological Targets

Associated Conditions

Avacopan

Pricing & Availability

Product Information

Biological Profile

Safety Information

Properties

Biological Targets

Associated Conditions

Documentation

Avacopan

Pricing & Availability

Product Information

Biological Profile

Safety Information

Properties

Biological Targets

Associated Conditions

Related Articles

Avacopan for the treatment of ANCA-associated vasculitis.

Management of primary vasculitides with biologic and novel small molecule medications.

Avacopan offers alternative to steroids for ANCA-associated vasculitis.

Evaluation of the Safety and Efficacy of Avacopan, a C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Treated Concomitantly With Rituximab or Cyclophosphamide/Azathioprine: Protocol for a Randomized, Double-Blind, Active-Controlled, Phase 3 Trial.

Avacopan

Pricing & Availability

Product Information

Biological Profile

Safety Information

Properties

Biological Targets

Associated Conditions

Related Articles

Avacopan for the treatment of ANCA-associated vasculitis.

Management of primary vasculitides with biologic and novel small molecule medications.

Avacopan offers alternative to steroids for ANCA-associated vasculitis.

Evaluation of the Safety and Efficacy of Avacopan, a C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Treated Concomitantly With Rituximab or Cyclophosphamide/Azathioprine: Protocol for a Randomized, Double-Blind, Active-Controlled, Phase 3 Trial.

Documentation